Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

BeiGene

DB:49B
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
49B
DB
$11B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People’s Republic of China, the United States, and internationally. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • BeiGene has significant price volatility in the past 3 months.
49B Share Price and Events
7 Day Returns
6.9%
DB:49B
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-5.5%
DB:49B
-13.2%
DE Biotechs
-20.9%
DE Market
49B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BeiGene (49B) 6.9% -10.6% -17% -5.5% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 49B outperformed the Biotechs industry which returned -13.2% over the past year.
  • 49B outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
49B
Industry
5yr Volatility vs Market

49B Value

 Is BeiGene undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BeiGene to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BeiGene.

DB:49B Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 19 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:49B
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 25%) (2.55%))
1.141
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.141 * 6.33%)
6.83%

Discounted Cash Flow Calculation for DB:49B using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BeiGene is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:49B DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.83%)
2020 -1,158.40 Analyst x5 -1,084.31
2021 -703.29 Analyst x7 -616.20
2022 -620.40 Analyst x5 -508.81
2023 75.82 Analyst x4 58.21
2024 388.67 Analyst x3 279.28
2025 629.91 Est @ 62.07% 423.68
2026 902.87 Est @ 43.33% 568.43
2027 1,175.67 Est @ 30.22% 692.84
2028 1,422.96 Est @ 21.03% 784.94
2029 1,630.81 Est @ 14.61% 842.05
Present value of next 10 years cash flows $1,440.00
DB:49B DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $1,630.81 × (1 + -0.39%) ÷ (6.83% – -0.39%)
$22,489.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $22,489.09 ÷ (1 + 6.83%)10
$11,611.97
DB:49B Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,440.00 + $11,611.97
$13,051.97
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $13,051.97 / 77.66
$168.06
DB:49B Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:49B represents 0.06644x of NasdaqGS:BGNE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.06644x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 168.06 x 0.06644
€11.17
Value per share (EUR) From above. €11.17
Current discount Discount to share price of €9.30
= -1 x (€9.30 - €11.17) / €11.17
16.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BeiGene is available for.
Intrinsic value
17%
Share price is €9.3 vs Future cash flow value of €11.17
Current Discount Checks
For BeiGene to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BeiGene's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • BeiGene's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BeiGene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BeiGene's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:49B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-15.80
NasdaqGS:BGNE Share Price ** NasdaqGS (2020-04-03) in USD $139.98
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BeiGene.

DB:49B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BGNE Share Price ÷ EPS (both in USD)

= 139.98 ÷ -15.80

-8.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BeiGene is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BeiGene is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BeiGene's expected growth come at a high price?
Raw Data
DB:49B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts
36.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BeiGene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BeiGene's assets?
Raw Data
DB:49B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $15.61
NasdaqGS:BGNE Share Price * NasdaqGS (2020-04-03) in USD $139.98
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:49B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BGNE Share Price ÷ Book Value per Share (both in USD)

= 139.98 ÷ 15.61

8.97x

* Primary Listing of BeiGene.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BeiGene is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BeiGene's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BeiGene has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

49B Future Performance

 How is BeiGene expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BeiGene expected to grow at an attractive rate?
  • BeiGene's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • BeiGene's earnings growth is expected to exceed the Germany market average.
  • BeiGene's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:49B Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:49B Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts 36.9%
DB:49B Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts 34%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:49B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:49B Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 2,575 464 319 5
2023-12-31 2,002 -138 -151 7
2022-12-31 1,373 -688 -563 12
2021-12-31 753 -717 -904 18
2020-12-31 358 -1,108 -1,299 19
2020-04-05
DB:49B Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 428 -750 -949
2019-09-30 430 -677 -829
2019-06-30 434 -544 -665
2019-03-31 244 -615 -737
2018-12-31 198 -548 -674
2018-09-30 158 -260 -505
2018-06-30 324 -121 -243
2018-03-31 271 -56 -147
2017-12-31 238 13 -93
2017-09-30 220 -107 -31
2017-06-30 0 -138 -184
2017-03-31 0 -105 -148

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BeiGene's earnings are expected to grow significantly at over 20% yearly.
  • BeiGene's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:49B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below

All data from BeiGene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:49B Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.16 23.98 -1.76 5.00
2023-12-31 -2.78 8.87 -10.16 6.00
2022-12-31 -7.24 0.31 -15.32 8.00
2021-12-31 -13.84 -1.57 -19.40 8.00
2020-12-31 -17.95 -1.44 -27.89 9.00
2020-04-05
DB:49B Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -15.80
2019-09-30 -13.87
2019-06-30 -11.29
2019-03-31 -12.83
2018-12-31 -12.15
2018-09-30 -9.72
2018-06-30 -5.05
2018-03-31 -3.29
2017-12-31 -2.23
2017-09-30 -0.80
2017-06-30 -4.97
2017-03-31 -4.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BeiGene will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess BeiGene's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BeiGene has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

49B Past Performance

  How has BeiGene performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BeiGene's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BeiGene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BeiGene's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BeiGene's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BeiGene's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BeiGene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:49B Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 428.21 -948.63 388.25
2019-09-30 429.99 -828.82 317.39
2019-06-30 434.05 -665.50 261.20
2019-03-31 243.51 -736.81 224.12
2018-12-31 198.22 -673.77 195.39
2018-09-30 157.72 -504.84 150.31
2018-06-30 323.74 -243.42 117.13
2018-03-31 270.93 -147.08 82.75
2017-12-31 238.39 -93.11 62.60
2017-09-30 220.21 -31.38 43.52 -5.18
2017-06-30 0.00 -184.26 32.61
2017-03-31 0.39 -147.84 25.73
2016-12-31 1.07 -119.22 20.10
2016-09-30 5.75 -108.87 14.71 5.18
2016-06-30 7.13 -87.37 12.01
2016-03-31 8.11 -68.89 9.31
2015-12-31 8.82 -57.10 7.31
2015-09-30 5.52 -33.60 5.99
2015-06-30 10.64 -29.36 7.77
2015-03-31 11.84 -26.11 7.31
2014-12-31 13.04 -18.28 6.93
2013-12-31 11.15 -7.49 3.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BeiGene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BeiGene has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BeiGene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BeiGene's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BeiGene has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

49B Health

 How is BeiGene's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BeiGene's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BeiGene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BeiGene's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BeiGene's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BeiGene Company Filings, last reported 3 months ago.

DB:49B Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 978.36 240.70 982.74
2019-09-30 1,294.24 255.69 1,231.92
2019-06-30 1,571.26 247.55 1,537.75
2019-03-31 1,622.68 241.59 1,613.66
2018-12-31 1,753.65 198.40 1,781.45
2018-09-30 1,983.43 195.97 2,033.76
2018-06-30 1,226.67 209.75 1,369.63
2018-03-31 1,358.72 173.68 1,464.02
2017-12-31 684.23 164.72 837.52
2017-09-30 764.49 158.35 757.44
2017-06-30 270.17 152.73 407.43
2017-03-31 308.42 19.90 327.48
2016-12-31 352.91 17.28 368.17
2016-09-30 187.83 18.03 203.62
2016-06-30 220.05 10.55 226.62
2016-03-31 243.10 6.21 247.23
2015-12-31 74.32 20.79 100.49
2015-09-30 100.08 20.63 121.34
2015-06-30 109.91 14.05 126.67
2015-03-31 25.77 13.84 44.40
2014-12-31 25.77 13.84 44.40
2013-12-31 -36.96 35.98 3.93
  • BeiGene's level of debt (24.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (53.7% vs 24.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BeiGene has sufficient cash runway for 1.1 years based on current free cash flow.
  • BeiGene has less than a year of cash runway if free cash flow continues to grow at historical rates of 60.4% each year.
X
Financial health checks
We assess BeiGene's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BeiGene has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

49B Dividends

 What is BeiGene's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BeiGene dividends. Estimated to be 0% next year.
If you bought €2,000 of BeiGene shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BeiGene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BeiGene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:49B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:49B Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 4.00
2020-12-31 0.00 4.00
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BeiGene has not reported any payouts.
  • Unable to verify if BeiGene's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BeiGene's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BeiGene has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BeiGene's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BeiGene's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BeiGene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BeiGene has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

49B Management

 What is the CEO of BeiGene's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Oyler
COMPENSATION $27,895,819
AGE 51
TENURE AS CEO 10.3 years
CEO Bio

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009. He co-founded Telephia, Inc. (now Nielsen Mobile, Inc.) and served as its President from 1997 to 2002. He served as Chief Executive Officer of Galenea Corp. from 2002 to 2004. Mr. Oyler served as the Co-Chief Executive Officer of Genta, Inc., from 1997 to 1998. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler serves as the Chairman at BeiGene, Ltd. and has been its Director since October 2010. Mr. Oyler earned an MBA from the Stanford Graduate School of Business and a Bachelor of Science degree in Mechanical Engineering from MIT.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BeiGene management team in years:

7.1
Average Tenure
56
Average Age
  • The average tenure for the BeiGene management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

John Oyler

TITLE
Co-Founder
COMPENSATION
$28M
AGE
51
TENURE
10.3 yrs

Xiaobin Wu

TITLE
GM of China & President
COMPENSATION
$22M
AGE
57
TENURE
1.9 yrs

Xiaodong Wang

TITLE
Co-Founder
COMPENSATION
$6M
AGE
56
TENURE
10.3 yrs

Howard Liang

TITLE
CFO & Chief Strategy Officer
COMPENSATION
$4M
AGE
56
TENURE
4.8 yrs

Jane Huang

TITLE
Chief Medical Officer of Hematology
COMPENSATION
$3M
AGE
46
TENURE
3.6 yrs

Daniel Maller

TITLE
Vice President of Finance & Accounting

Lucy Li

TITLE
Investor Contact

Scott Samuels

TITLE
Senior VP & General Counsel

Luo Lusong

TITLE
Head of Discovery Biology & Senior VP
TENURE
9.5 yrs

Steve Young

TITLE
Acting Head of Medicinal Chemistry
Board of Directors Tenure

Average tenure and age of the BeiGene board of directors in years:

4.2
Average Tenure
53.5
Average Age
  • The tenure for the BeiGene board of directors is about average.
Board of Directors

Xiaodong Wang

TITLE
Co-Founder
COMPENSATION
$6M
AGE
56
TENURE
9.3 yrs

Donald Glazer

TITLE
Independent Non-Executive Director
COMPENSATION
$359K
AGE
75
TENURE
7.2 yrs

John Oyler

TITLE
Co-Founder
COMPENSATION
$28M
AGE
51

Michael Yi

TITLE
Independent Non-Executive Director & Member of the Scientific Advisory Committee
COMPENSATION
$374K
AGE
47
TENURE
0.2 yrs

Thomas Malley

TITLE
Independent Non-Executive Director & Member of the Scientific Advisory Committee
COMPENSATION
$369K
AGE
50
TENURE
0.2 yrs

Tony Hooper

TITLE
Independent Non Executive Director & Chairman of the Commercial Advisory Committee
AGE
64
TENURE
0.2 yrs

Michael Goller

TITLE
Independent Non-Executive Director & Member of the Scientific Advisory Committee
COMPENSATION
$352K
AGE
44
TENURE
5 yrs

Ranjeev Krishana

TITLE
Independent Non-Executive Director & Member of the Commercial Advisory Committee
COMPENSATION
$355K
AGE
45
TENURE
5.5 yrs

Timothy Chen

TITLE
Independent Non-Executive Director & Member of the Commercial Advisory Committee
COMPENSATION
$362K
AGE
63
TENURE
4.2 yrs

Sam Su

TITLE
Independent Non-Executive Director & Member of the Commercial Advisory Committee
COMPENSATION
$502K
AGE
67
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Mar 20 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 12. Mar 20 12. Mar 20 1,093,372 €10.19 €11,142,549
26. Feb 20 Buy Capital Research and Management Company Company 24. Feb 20 24. Feb 20 1,411,384 €150.24 €212,050,991
31. Jan 20 Buy Capital Research and Management Company Company 29. Jan 20 29. Jan 20 1,308,869 €11.13 €14,573,507
08. Jan 20 Sell Capital Research and Management Company Company 06. Jan 20 06. Jan 20 -25,571 €144.87 €-3,704,499
03. Jan 20 Buy Capital Research and Management Company Company 30. Dec 19 30. Dec 19 128,531 €143.64 €18,462,421
22. Oct 19 Sell Capital Research and Management Company Company 18. Oct 19 18. Oct 19 -383,578 €119.00 €-45,644,787
17. Oct 19 Buy Capital Research and Management Company Company 11. Oct 19 11. Oct 19 367,549 €108.04 €39,709,590
28. Sep 19 Buy Capital Research and Management Company Company 26. Sep 19 26. Sep 19 1,958,163 €9.22 €18,053,556
17. Aug 19 Buy Capital Research and Management Company Company 14. Aug 19 14. Aug 19 474,077 €9.34 €4,429,622
13. Apr 19 Buy Capital Research and Management Company Company 11. Apr 19 11. Apr 19 44,719 €16.04 €717,169
02. Jul 19 Sell Heng Liang Individual 27. Jun 19 27. Jun 19 -5,876 €8.33 €-48,963
16. May 19 Buy Donald Glazer Individual 13. May 19 13. May 19 195,351 €1.09 €213,240
03. May 19 Sell John Oyler Individual 01. May 19 01. May 19 -36,712 €8.56 €-314,371
X
Management checks
We assess BeiGene's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BeiGene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

49B News

Simply Wall St News

49B Company Info

Description

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People’s Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company’s clinical stage drug candidates include BGB-3111, a small molecule Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; CC-122, a cereblon modulator; and BGB-3245, an oral small molecule inhibitor of specific BRAF mutations, including B-RAF non-V600 mutations and RAF fusions for various solid tumor indications. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the People’s Republic of China.

Details
Name: BeiGene, Ltd.
49B
Exchange: DB
Founded: 2010
$10,076,493,972
77,662,359
Website: http://www.beigene.com
Address: BeiGene, Ltd.
No.30 Science Park Road,
Zhong-Guan-Cun Life Science Park,
Beijing,
102206,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BGNE SPON ADS EACH REPR 13 ORD Nasdaq Global Select US USD 03. Feb 2016
DB 49BA SPON ADS EACH REPR 13 ORD Deutsche Boerse AG DE EUR 03. Feb 2016
BMV BGNE N SPON ADS EACH REPR 13 ORD Bolsa Mexicana de Valores MX MXN 03. Feb 2016
SEHK 6160 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 08. Aug 2018
DB 49B Ordinary Shares Deutsche Boerse AG DE EUR 08. Aug 2018
Number of employees
Current staff
Staff numbers
3,500
BeiGene employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 22:15
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.